Sugi Predict

Sugi Predict / Compounds / SCHEMBL265954

SCHEMBL265954

SCHEMBL265954

Cc1cnc(Cl)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 11/20 0.59
▸ JAK1 P23458 8/20 0.59
▸ JAK2 O60674 6/20 0.59
▸ JAK3 P52333 4/20 0.59
▸ RET P07949 2/20 0.59
▸ WEE1 P30291 2/20 0.59
▸ FLT3 P36888 2/20 0.59
▸ BRDT Q58F21 2/20 0.59
▸ ALK Q9UM73 2/20 0.59
▸ BUB1B O60566 1/20 0.59
▸ BRD2 P25440 1/20 0.59
▸ BRD3 Q15059 1/20 0.59
▸ HDAC1 Q13547 6/20 0.56
▸ TYK2 P29597 3/20 0.55
▸ NUAK1 O60285 2/20 0.55
▸ TNNI3K Q59H18 2/20 0.55
▸ BMPR1B O00238 1/20 0.55
▸ PLK4 O00444 1/20 0.55
▸ STK25 O00506 1/20 0.55
▸ CIT O14578 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29439998 1.00 BRD4 (0.59) BRD4JAK1JAK2JAK3RET
SCHEMBL30306511 0.90 BRD4 (0.63) BRD4JAK1JAK2JAK3RET
SCHEMBL18758023 0.90 BRD4 (0.63) BRD4JAK1JAK2JAK3RET
SCHEMBL30306489 0.88 BRD4 (0.52) BRD4JAK1JAK2JAK3RET
SCHEMBL30763999 0.88 BRD4 (0.52) BRD4JAK1JAK2JAK3RET
SCHEMBL29176792 0.88 BRD4 (0.52) BRD4JAK1JAK2JAK3RET
SCHEMBL25382998 0.87 BRD4 (0.74) BRD4JAK1JAK2JAK3RET
SCHEMBL30565204 0.87 BRD4 (0.74) BRD4JAK1JAK2JAK3RET
SCHEMBL30565206 0.87 BRD4 (0.74) BRD4JAK1JAK2JAK3RET
SCHEMBL30306430 0.87 BRD4 (0.61) BRD4JAK1JAK2JAK3RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745138-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-05-20 — — EP disclosed
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 — — EP disclosed
US-12391676-B2 BRD4-JAK2 inhibitors H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2025-08-19 — — US disclosed
US-20250188041-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA Trustlife Global Inc. 2025-06-12 — — US disclosed
WO-2024245443-A1 COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-12-05 — — WO disclosed
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 — — EP disclosed
WO-2024188209-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-09-19 — — WO disclosed
US-20240293406-A1 COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS IMPACT BIOMEDICINES INC (US) 2024-09-05 — — US disclosed
CN-113754591-B HDAC, JAK and BET three-target inhibitor and preparation method and application thereof 山东大学 2024-01-05 — — CN disclosed
WO-2023166153-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA BASH BIOTECH INC (US) 2023-09-07 — — WO disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 BRD4 142/4885JAK1 4/4885JAK2 1/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 BRD4 142/4885JAK1 4/4885JAK2 1/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 BRD4 142/4885JAK1 4/4885JAK2 1/4885
US-20250188041-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA RCC2, GLS, VHL BRD4 2186/4885JAK1 2901/4885JAK2 1549/4885
US-12391676-B2 BRD4-JAK2 inhibitors BRD4, BICRA, JAK2 BRD4 1/4885JAK1 23/4885JAK2 3/4885
US-20240293406-A1 COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS JAK2, NPM1, MCL1 BRD4 39/4885JAK1 113/4885JAK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.